AxoGen, Inc. (NASDAQ:AXGN) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET

Company Participants

Ed Joyce - Director, IR

Karen Zaderej - Chairman, President & CEO

Peter Mariani - EVP & CFO

Erick DeVinney - VP of Peripheral Nerve Science & Clinical Innovation

Conference Call Participants

Erin Fahey - SVB Leerink

Frank Pinal - Jefferies

Ross Osborn - Cantor Fitzgerald

Dave Turkaly - JMP Securities

Operator

Good day, ladies and gentlemen, and welcome to the AxoGen, Inc. Reports First Quarter Earnings Call. [Operator Instructions]

At this time, it is my pleasure to turn the floor over to your host, Ed Joyce. Sir, the floor is yours.

Ed Joyce

Thank you, Dagmar, and good afternoon, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President; Erick DeVinney, Vice President of Peripheral Nerve Science and Clinical Innovation; and Pete Mariani, Executive Vice President and Chief Financial Officer. Karen will discuss the quarter and our outlook for the year, Erick will discuss the RECON study and top line results, and Pete will provide an analysis of our financial performance, followed by closing remarks from Karen, and a question-and-answer Session.

Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen website. Within an hour following the end of the live call, a replay will be available on the Investor section of the company's website at www@axogeninc.com. Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include without limitation, statements related to the expected impact of COVID-19 and hospital staffing on our business, statements regarding our growth, our financial guidance, product development, product potential, expected clinical enrollment timing and outcomes, regulatory processes and approval, APC renovation timing and expense, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of internal controls or financial reporting, our visibility ads and sponsorship of conferences and educational events, global business disruptions caused by Russia's invasion of Ukraine and related sanctions and other matters not within our control.